RegulationSILVER SPRING, Md. · Event February 6, 2026
FDA says it will act against mass-marketed compounded GLP-1s
The statement warned of seizure and injunction 'without further notice' and set out claims compounders may not make.
FDA Commissioner Martin Makary issued a statement on February 6, 2026 announcing the agency’s “intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs.”
The statement said the actions “are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.”
The claims FDA ruled out
The statement tied the move to the advertising warning letters sent “in the fall of 2025” (our report on the September letters). It set out what companies may not say in promotional materials:
- that non-approved compounded products “are generic versions or the same as drugs approved by FDA”;
- that compounded drugs “use the same active ingredient as the FDA-approved drugs”;
- that compounded drugs “are clinically proven to produce results for the patient.”
The enforcement warning
The statement closed with a direct warning: “failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.” That language applies to “entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products.”
FDA’s page does not describe how it would restrict the APIs (for example, through import controls or supplier actions). We have not seen a later FDA document setting out the mechanism, and we will add one if it is published.
Context
The shortage exception that had allowed mass compounding of semaglutide and tirzepatide ended in early 2025 (tirzepatide, semaglutide). Compounding that continued had to rely on narrower grounds, such as a prescriber-documented clinical difference for a patient (explainer). This statement targets the marketing of those products as equivalents of Ozempic, Wegovy, Mounjaro or Zepbound.
FDA’s page lists Makary’s tenure as commissioner as “April 2025 - May 2026.” By October 2026, correspondence on peptide policy was addressed to Acting Commissioner Kyle Diamantas (report).
What changed: key dates
| Date | What happened |
|---|---|
| U.S. FDA: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs | |
| Healio: FDA to act against use of GLP-1 active pharmaceutical ingredients in non-approved drugs | |
| Event date for this report | |
| Amino Wire published this report |
Sources
2 linked records- [1] FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs U.S. FDA · Primary record
- [2] FDA to act against use of GLP-1 active pharmaceutical ingredients in non-approved drugs Healio ·
Amino Wire reports regulatory and court records. Nothing here is medical or legal advice, and we do not provide dosing information. Named companies may respond; see right of reply.
